Form 4: Elevation Oncology CEO Joseph Ferra Jr. Reports Stock Transactions
SEC Form 4 Filing
Elevation Oncology's CEO, Joseph Ferra Jr., reported the disposition of shares to cover tax obligations upon the vesting of restricted stock units.
Summary
- On March 16, 2024, Joseph J. Ferra Jr., CEO of Elevation Oncology, reported transactions involving the company's common stock.
- Ferra disposed of 12,562 shares to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs).
- Additionally, 4,773 shares were disposed of at a price of $4.39.
- Following these transactions, Ferra directly owns 85,680 shares of Elevation Oncology common stock and 62,809 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by an insider. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for reporting insider transactions and provide transparency to investors.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in insider ownership.
Key Dates
| Date | Description |
|---|---|
| June 16, 2022 | 25% of the RSUs vested. |
| March 16, 2024 | Date of stock transactions and RSU vesting. |
| March 19, 2024 | Date of report signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.